차세대 조직 바이오마커 시장 : 규모, 점유율 및 동향 분석 보고서 - 제품별, 유형별, 기술별, 용도별, 최종 용도별, 지역별 부문 예측(2025-2030년)

Next Generation Tissue Biomarkers Market Growth & Trends:

The global next generation tissue biomarkers market size is anticipated to reach USD 5.98 billion by 2030 and is projected to grow at a CAGR of 12.74% during the forecast period, according to a new report by Grand View Research, Inc. Key driving factors such as increasing prevalence of chronic diseases, technological advancements in biomarker detection techniques, and rising demand for personalized medicines are responsible for market growth. There is a global increase in the incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases.

Increasing technological advancements for detecting next generation tissue biomarkers boost the growth of the market. The development of high throughput screening technologies such as next-generation sequencing (NGS) has significantly enhanced the ability to analyze genetic mutations and gene expression profiles in cancer tissues. Furthermore, liquid biopsies, high throughput screening technologies, epigenetic profiling, and microRNA-based biosensors are in practice for next generation tissue biomarker detection. Collectively, these technological advancements are transforming the landscape of tissue biomarker discovery, leading to more accurate diagnostics, personalized treatment strategies, and improved patient outcomes. AI and machine learning algorithms are being incorporated into digital pathology, automating the analysis of tissue images. The growing demand for personalized medicines is another key factor responsible for market growth. These personalized medicines are increasingly leveraging next-generation tissue biomarkers to tailor treatments to individual patients.

For the detection of biomarkers, in February 2025, Alida Biosciences (AlidaBio), a company in epigenomic research tools, officially announced the full commercial launch of its EpiPlex platform. This groundbreaking platform is the first to simultaneously detect and quantify multiple RNA modifications through short-read sequencing while also providing gene expression data.

In February 2025, Biofidelity, a provider of genomic solutions, unveiled details about the launch of Enspyre, an innovative target enrichment technology with a wide range of potential applications. A groundbreaking target enrichment technology that greatly improves next-generation sequencing (NGS) efficiency by selectively eliminating background DNA.

In September 2024, Genialis, an RNA biomarker company, announced the launch of Genialis krasID, the first biomarker algorithm capable of predicting patient response and clinical benefit to KRAS inhibitors (KRASi) across different tissue histologies and mutation types. Genialis krasID can assist in guiding drug development from early preclinical stages, such as compound/MOA differentiation and selection, to clinical trials.

Another novel senescent cell targeting molecules was developed in October 2024. Illumina, Inc., a company in DNA sequencing and array-based technologies, introduced its MiSeq i100 Series of sequencing systems today, offering unmatched benchtop speed and ease of use to enhance next-generation sequencing (NGS) in laboratories.

In September 2021, Roche announced the release of the AVENIO Tumor Tissue CGP Kit. This new kit enhances the existing CGP portfolio from Roche and Foundation Medicine, enabling laboratories to conduct more extensive oncology research in-house. The introduction of this kit will greatly increase global access to genomic profiling by offering an in-house solution for those unable to access our tests through centralized laboratories, the company stated.

Next Generation Tissue Biomarkers Market Report Highlights:

• Based on product, reagents and assays accounted for the largest revenue share of 55.97% in 2024. This segment is expected to see rapid expansion due to its broad applicability in biopharmaceutical research. A key driving factor is the growing need for early disease detection and diagnostics, which has resulted in high demand for accurate, reliable, and rapid diagnostics, contributing to market growth.
• Based on type, the genomic biomarker segment dominated the market in 2024 owing to the rising demand for innovative therapies, growing competition for early disease detection, and significant R&D investments. Metabolomic biomarkers are expected to grow fastest over the forecast period. Metabolomic biomarkers refer to specific metabolic changes or substances in the body that can be measured and used to identify disease states, predict disease risk, and monitor responses to treatments.
• Based on technology, the next generation sequencing segment dominated the market with the largest revenue share in 2024. Next Generation Sequencing (NGS) refers to the huge DNA sequencing methods that aid in genomic discovery. The spatial genomics biology segment is anticipated to witness growth at the fastest CAGR from 2024 to 2030. The advancements in genome editing tools, such as the CRISPR/Cas9 system, have facilitated spatial genomics biology adoption, driving market growth.
• Based on application, the oncology segment dominated the market with the largest revenue share in 2024. The growing demand for precision medicine drives the segment growth and targeted cancer therapies. Companion diagnostics are expected to grow fastest over the forecast period. The companion diagnostics market is experiencing significant product expansion, with new assays being developed for various cancer types, autoimmune diseases, and neurological disorders.
• Based on end use, the hospitals & reference labs segment dominated the market with the largest revenue share in 2024. Hospitals and reference labs are rapidly adopting next generation tissue biomarkers to enhance efficiency, accuracy, and accessibility. Contract research organizations are projected to grow significantly during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Technology
  • 1.2.3. Application
  • 1.2.4. Type
  • 1.2.5. End Use
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Application outlook
  • 2.2.4. Type outlook
  • 2.2.5. End Use outlook
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Next Generation Tissue Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rise of Precision Medicine and Companion Diagnostics
    • 3.2.1.2. Technological Advancements in Spatial Biology and NGS
    • 3.2.1.3. Expansion of Clinical Utility Across Disease Areas
    • 3.2.1.4. Growth in Digital Pathology and AI-Driven Analysis
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Multi-Omic Platforms and Reagents
    • 3.2.2.2. Data Privacy and Infrastructure Barriers in AI Adoption
• 3.3. Next Generation Tissue Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Next Generation Tissue Biomarkers Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Next Generation Tissue Biomarkers Market: Product Movement Analysis
• 4.3. Next Generation Tissue Biomarkers Market Size & Trend Analysis, by product, 2018 to 2030 (USD Million)
• 4.4. Reagents & Assays
  • 4.4.1. Reagents & Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Instruments & Platforms
  • 4.5.1. Instruments & Platforms Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Software & AI
  • 4.6.1. Software & AI Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Next Generation Tissue Biomarkers Market: Type Estimates & Trend Analysis

• 5.1. Type Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Next Generation Tissue Biomarkers Market by Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Genomic Biomarkers
  • 5.5.1. Genomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Proteomic Biomarkers
  • 5.6.1. Proteomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Proteomic Biomarkers
  • 5.7.1. Proteomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Epigenetic Biomarkers
  • 5.8.1. Epigenetic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Transcriptomic Biomarkers
  • 5.9.1. Transcriptomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.10. Metabolomic Biomarkers
  • 5.10.1. Metabolomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Next Generation Tissue Biomarkers Market: Technology Estimates & Trend Analysis

• 6.1. Technology Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Next Generation Tissue Biomarkers Market by Technology Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Immunohistochemistry
  • 6.5.1. Immunohistochemistry Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Next-Generation Sequencing (NGS)
  • 6.6.1. Next-Generation Sequencing (NGS) Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Mass Spectrometry (MS)-based Proteomics
  • 6.7.1. Mass Spectrometry (MS)-based Proteomics Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Spatial Biology Platforms
  • 6.8.1. Spatial Biology Platforms Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Digital Pathology & AI Analysis
  • 6.9.1. Digital Pathology & AI Analysis Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.10. Others
  • 6.10.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Next Generation Tissue Biomarkers Market: Application Estimates & Trend Analysis

• 7.1. Application Market Share, 2024 & 2030
• 7.2. Segment Dashboard
• 7.3. Next Generation Tissue Biomarkers Market by Application Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Oncology
  • 7.5.1. Oncology Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Companion Diagnostics
  • 7.6.1. Companion Diagnostics Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Drug Discovery & Development
  • 7.7.1. Drug Discovery & Development Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Neurology
  • 7.8.1. Neurology Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. Others
  • 7.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Next Generation Tissue Biomarkers Market: End Use Estimates & Trend Analysis

• 8.1. End Use Market Share, 2024 & 2030
• 8.2. Segment Dashboard
• 8.3. Next Generation Tissue Biomarkers Market by End Use Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 8.5. Hospitals & Reference Labs
  • 8.5.1. Hospitals & Reference Labs Market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Pharma & Biotech Companies
  • 8.6.1. Pharma & Biotech Companies Market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Academic and Research Institutes
  • 8.7.1. Academic and Research Institutes Market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Contract Research Organizations (CROs)
  • 8.8.1. Contract Research Organizations (CROs) Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Next Generation Tissue Biomarkers Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.5. North America
  • 9.5.1. North America
  • 9.5.2. U.S.
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/Reimbursement
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. Canada
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/Reimbursement
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. Mexico
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/Reimbursement
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Europe
  • 9.6.1. Europe
  • 9.6.2. UK
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/Reimbursement
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. Germany
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/Reimbursement
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. France
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/Reimbursement
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. Italy
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/Reimbursement
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. Spain
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework/Reimbursement
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.7. Norway
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/Reimbursement
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.8. Sweden
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework/Reimbursement
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.9. Denmark
    • 9.6.9.1. Key country dynamics
    • 9.6.9.2. Regulatory framework/Reimbursement
    • 9.6.9.3. Competitive scenario
    • 9.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Asia Pacific
  • 9.7.1. Asia Pacific
  • 9.7.2. Japan
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/Reimbursement
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. China
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/Reimbursement
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. India
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/Reimbursement
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.5. Australia
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/Reimbursement
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.6. South Korea
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/Reimbursement
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.7. Thailand
    • 9.7.7.1. Key country dynamics
    • 9.7.7.2. Regulatory framework/Reimbursement
    • 9.7.7.3. Competitive scenario
    • 9.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. Latin America
  • 9.8.1. Latin America
  • 9.8.2. Brazil
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework/Reimbursement
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.3. Argentina
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework/Reimbursement
    • 9.8.3.3. Competitive scenario
    • 9.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.9. MEA
  • 9.9.1. MEA
  • 9.9.2. South Africa
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/Reimbursement
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.3. Saudi Arabia
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/Reimbursement
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.4. UAE
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/Reimbursement
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.5. Kuwait
    • 9.9.5.1. Key country dynamics
    • 9.9.5.2. Regulatory framework
    • 9.9.5.3. Competitive scenario
    • 9.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2024
  • 10.3.4. Roche Diagnostics / Ventana Medical Systems
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Services benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Agilent Technologies / Dako
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Services benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Thermo Fisher Scientific
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Services benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Leica Biosystems (Danaher Corporation)
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Services benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Illumina
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Services benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Qiagen
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Services benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. NeoGenomics
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Services benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. NanoString Technologies
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Services benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Akoya Biosciences
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Services benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. Bio-Techne / ACD
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Services benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Guardant Health
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Services benchmarking
    • 10.3.14.4. Strategic initiatives